Systemic immunotoxin therapy of cancer: advances and prospects.
作者信息
Wawrzynczak E J
机构信息
Drug Targeting Laboratory, Institute of Cancer Research, Sutton, Surrey, UK.
出版信息
Br J Cancer. 1991 Oct;64(4):624-30. doi: 10.1038/bjc.1991.374.
Abstract
摘要
相似文献
1
Systemic immunotoxin therapy of cancer: advances and prospects.
Br J Cancer. 1991 Oct;64(4):624-30. doi: 10.1038/bjc.1991.374.
2
A monoclonal immunotoxin against laryngeal carcinoma cells.
Otolaryngol Pol. 1990;44(3):214-5.
3
Anti-tumor activity of a blocked ricin immunotoxin with specificity against the cluster-5A antigen associated with human small-cell lung cancer.
Int J Cancer. 1993 Jul 30;54(6):1028-35. doi: 10.1002/ijc.2910540628.
4
Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer.
Cancer Res. 1989 Nov 1;49(21):6153-60.
5
MDX RA 4197X-RA, monoclonal antibody ricin A.
Drugs R D. 2002;3(2):111-2. doi: 10.2165/00126839-200203020-00008.
6
Inhibition of growth of human tumor xenografts in athymic mice treated with ricin toxin A chain-monoclonal antibody 791T/36 conjugates.
Cancer Res. 1987 Oct 1;47(19):5042-6.
7
Therapy of metastatic malignant melanoma using Xomazyme Mel, a murine monoclonal anti-melanoma ricin A chain immunotoxin.
Int J Rad Appl Instrum B. 1989;16(6):625-7. doi: 10.1016/0883-2897(89)90085-8.
8
Immunotoxin therapy of cancer.
Oncology (Williston Park). 1993 May;7(5):69-78; discussion 79-80, 83-6.
9
Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin.
J Neurosurg. 1987 Jun;66(6):850-61. doi: 10.3171/jns.1987.66.6.0850.
10
Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin.
Leuk Lymphoma. 1997 Jul;26(3-4):287-98. doi: 10.3109/10428199709051778.
引用本文的文献
1
Macromolecular Conjugate and Biological Carrier Approaches for the Targeted Delivery of Antibiotics.
Antibiotics (Basel). 2017 Jul 4;6(3):14. doi: 10.3390/antibiotics6030014.
2
Reduced antibody response to streptavidin through site-directed mutagenesis.
Protein Sci. 2001 Mar;10(3):491-503. doi: 10.1110/ps.19901.
3
Prodrugs in Cancer Chemotherapy.
Pathol Oncol Res. 1997;3(4):309-324. doi: 10.1007/BF02904292.
4
Immunoconjugates made of an anti-EGF receptor monoclonal antibody and type 1 ribosome-inactivating proteins from Saponaria ocymoides or Vaccaria pyramidata.
Br J Cancer. 1997;75(6):822-8. doi: 10.1038/bjc.1997.147.
5
Distribution of radiolabelled anti-CA125 monoclonal antibody OC125-F(ab)2-fragment following resection guided by antibodies (REGAJ) in ovarian cancer patients.
J Clin Lab Anal. 1997;11(2):94-103. doi: 10.1002/(SICI)1098-2825(1997)11:2<94::AID-JCLA5>3.0.CO;2-K.
6
Application of fusogenic liposomes containing fragment A of diphtheria toxin to cancer therapy.
Br J Cancer. 1996 Feb;73(4):472-6. doi: 10.1038/bjc.1996.83.
7
Pharmacokinetic studies in mice with ICI D0490, a novel recombinant ricin A-chain immunotoxin.
Br J Cancer. 1993 Jun;67(6):1310-5. doi: 10.1038/bjc.1993.243.
8
Requirement of monocytes and T-helper cells during development of tumor cell cytotoxicity in targeted T cells.
Cancer Immunol Immunother. 1994 Jan;38(1):43-52. doi: 10.1007/BF01517169.
9
A critical comparison of three internalization assays applied to the evaluation of a given mAb as a toxin-carrier candidate.
Cancer Immunol Immunother. 1993 Jul;37(1):54-60. doi: 10.1007/BF01516942.
10
In vitro and in vivo properties of an anti-CD5-momordin immunotoxin on normal and neoplastic T lymphocytes.
Cancer Immunol Immunother. 1993 May;36(5):346-50. doi: 10.1007/BF01741174.
本文引用的文献
1
Drug-targeting by monoclonal antibodies.
Br J Cancer. 1987 Mar;55(3):227-31. doi: 10.1038/bjc.1987.44.
2
Redesigning nature's poisons to create anti-tumor reagents.
Science. 1987 Nov 20;238(4830):1098-104. doi: 10.1126/science.3317828.
3
Comparison of the pharmacokinetics and hepatotoxic effects of saporin and ricin A-chain immunotoxins on murine liver parenchymal cells.
Cancer Res. 1988 Dec 15;48(24 Pt 1):7072-8.
4
Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.
Cancer Res. 1988 Nov 15;48(22):6396-403.
5
Immunoconjugate generation between the ribosome inactivating protein restrictocin and an anti-human breast carcinoma MAB.
Cancer Immunol Immunother. 1988;26(2):114-20. doi: 10.1007/BF00205603.
6
In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
Cancer Res. 1988 May 1;48(9):2626-31.
7
8
An assay that predicts the ability of monoclonal antibodies to form potent ricin A chain-containing immunotoxins.
Cancer Res. 1988 Mar 1;48(5):1119-23.
9
The role of the diphtheria toxin receptor in cytosol translocation.
J Biol Chem. 1988 Jan 25;263(3):1295-300.
10
Ricin B chain-containing immunotoxins prepared with heat-denatured B chain lacking galactose-binding ability potentiate the cytotoxicity of a cell-reactive ricin A chain immunotoxin.
Biochim Biophys Acta. 1988 Aug 19;971(1):55-62. doi: 10.1016/0167-4889(88)90161-9.
Zotero 插件